Newborn screening for lysosomal storage disorders: Ethical and technical considerations

Peter J. Meikle, C. J. Dean, D. A. Brooks, J. J. Hopwood

Research output: Contribution to journalReview article

Abstract

Over recent years, significant progress has been made in the development of therapeutic options for lysosomal storage disorders. Currently, there are therapy options, either approved or in clinical trials, for over 75% of patients. The effectiveness of these therapies, particularly for those disorders involving central nervous system and bone pathologies, will rely heavily upon the early diagnosis and commencement of treatment, before the onset of irreversible pathology. In the absence of a family history, the only practical way to identify patients presymptomatically is through a newborn screening program. In this review, the ethical and technical issues associated with such a program are discussed.

LanguageEnglish
Pages305-311
Number of pages7
JournalItalian Journal of Pediatrics
Volume30
Issue number5
Publication statusPublished - 1 Oct 2004

Keywords

  • Biomarker
  • Early diagnosis
  • Lysosomal storage disorder
  • Newborn screening
  • Therapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Meikle, P. J., Dean, C. J., Brooks, D. A., & Hopwood, J. J. (2004). Newborn screening for lysosomal storage disorders: Ethical and technical considerations. Italian Journal of Pediatrics, 30(5), 305-311.
Meikle, Peter J. ; Dean, C. J. ; Brooks, D. A. ; Hopwood, J. J. / Newborn screening for lysosomal storage disorders : Ethical and technical considerations. In: Italian Journal of Pediatrics. 2004 ; Vol. 30, No. 5. pp. 305-311.
@article{70987989bc384ac1b3a2c22e4fff2b21,
title = "Newborn screening for lysosomal storage disorders: Ethical and technical considerations",
abstract = "Over recent years, significant progress has been made in the development of therapeutic options for lysosomal storage disorders. Currently, there are therapy options, either approved or in clinical trials, for over 75{\%} of patients. The effectiveness of these therapies, particularly for those disorders involving central nervous system and bone pathologies, will rely heavily upon the early diagnosis and commencement of treatment, before the onset of irreversible pathology. In the absence of a family history, the only practical way to identify patients presymptomatically is through a newborn screening program. In this review, the ethical and technical issues associated with such a program are discussed.",
keywords = "Biomarker, Early diagnosis, Lysosomal storage disorder, Newborn screening, Therapy",
author = "Meikle, {Peter J.} and Dean, {C. J.} and Brooks, {D. A.} and Hopwood, {J. J.}",
year = "2004",
month = "10",
day = "1",
language = "English",
volume = "30",
pages = "305--311",
journal = "Italian Journal of Pediatrics",
issn = "1720-8424",
publisher = "BioMed Central",
number = "5",

}

Meikle, PJ, Dean, CJ, Brooks, DA & Hopwood, JJ 2004, 'Newborn screening for lysosomal storage disorders: Ethical and technical considerations', Italian Journal of Pediatrics, vol. 30, no. 5, pp. 305-311.

Newborn screening for lysosomal storage disorders : Ethical and technical considerations. / Meikle, Peter J.; Dean, C. J.; Brooks, D. A.; Hopwood, J. J.

In: Italian Journal of Pediatrics, Vol. 30, No. 5, 01.10.2004, p. 305-311.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Newborn screening for lysosomal storage disorders

T2 - Italian Journal of Pediatrics

AU - Meikle, Peter J.

AU - Dean, C. J.

AU - Brooks, D. A.

AU - Hopwood, J. J.

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Over recent years, significant progress has been made in the development of therapeutic options for lysosomal storage disorders. Currently, there are therapy options, either approved or in clinical trials, for over 75% of patients. The effectiveness of these therapies, particularly for those disorders involving central nervous system and bone pathologies, will rely heavily upon the early diagnosis and commencement of treatment, before the onset of irreversible pathology. In the absence of a family history, the only practical way to identify patients presymptomatically is through a newborn screening program. In this review, the ethical and technical issues associated with such a program are discussed.

AB - Over recent years, significant progress has been made in the development of therapeutic options for lysosomal storage disorders. Currently, there are therapy options, either approved or in clinical trials, for over 75% of patients. The effectiveness of these therapies, particularly for those disorders involving central nervous system and bone pathologies, will rely heavily upon the early diagnosis and commencement of treatment, before the onset of irreversible pathology. In the absence of a family history, the only practical way to identify patients presymptomatically is through a newborn screening program. In this review, the ethical and technical issues associated with such a program are discussed.

KW - Biomarker

KW - Early diagnosis

KW - Lysosomal storage disorder

KW - Newborn screening

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=11144234003&partnerID=8YFLogxK

M3 - Review article

VL - 30

SP - 305

EP - 311

JO - Italian Journal of Pediatrics

JF - Italian Journal of Pediatrics

SN - 1720-8424

IS - 5

ER -